1

1	
2	
3	Bacterial shedding and serologic responses following an outbreak of Salmonella Typhi in an endemic
4	cohort.
5	
6	Peter Johnston ^{1*} , Patrick Bogue ² , Angeziwa Chunga Chirambo ² , Maurice Mbewe ² , Reenesh Prakash ² ,
7	Vanessa Kandoole-Kabwere ² , Rebecca Lester ² , Thomas Darton ¹ , Stephen Baker ³ , Melita Gordon ² ,
8	James Meiring ^{1,2}
9	
10	1. Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield,
11	United Kingdom.
12	2. Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi.
13	3. Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of
14	Cambridge, United Kingdom.
15	
16	*Corresponding author. E-mail: p.i.johnston@sheffield.ac.uk
17	Running title: Bacterial shedding and serologic responses after a typhoid outbreak.
18	
19	
20	
21	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

23 Background

Salmonella enterica serovar Typhi (S. Typhi), the causative agent of Typhoid fever, is transmitted
faecal-orally. Some typhoid sufferers shed S. Typhi beyond convalescence, but culturing stool
following every case is impractical. Here we hypothesised that serology might direct testing and
identify shedding after a typhoid outbreak.

28 Methodology/Principle Findings

29 In 2016 there was a typhoid outbreak in a Nursing School in Malosa, Malawi. We collected serum

30 three and six-months post-outbreak. We measured IgG antibody titres against Vi capsular

31 polysaccharide (anti-Vi IgG) and IgM / IgG antibodies against H:d flagellin (anti-H:d). We screened

32 faecal samples from participants with high and low anti-Vi IgG (measured at visit one) by culture and

33 PCR. Participants reported whether they had persistent fever for \geq three days (in keeping with World

Health Organization definitions for typhoid) during the outbreak. We tested for environmental *S*.

35 Typhi.

36 368 people provided serum at 3-months, of whom 320 provided serum at 6-months; 49 participants

37 provided a faecal sample (25 from the highest and 24 from the lowest deciles for anti-Vi IgG titre).

38 We did not grow *S*. Typhi from faeces, but one sample produced a positive PCR amplification for *S*.

39 Typhi. Median anti-Vi IgG titre fell amongst participants with persistent fever (8.08 to 3.7 EU/ml,

40 <0.000001, Wilcoxon signed rank). Median anti-H:d IgG titres fell in those with and without

41 persistent fever (87.8 to 77.4 EU/, $p = \langle 0.000001 \text{ and } 82.4 \text{ to } 79.2 \text{ EU/ml}, p = 0.0002$, Wilcoxon

42 signed rank, respectively). Anti-H:d IgM titres did not change significantly. Non-Typhoidal

43 Salmonellae were identified in water sampled at source and a kitchen tap.

44 Conclusions / Significance

We did not identify culture-confirmed shedding through sero-surveillance. Serologic trends signify a
fall from an outbreak-associated peak. Despite effective vaccines, identifying ways to detect and treat
shedding remain vital to break transmission and eliminate typhoid.

3

48 Author Summary

49	Typhoid fever spreads by the faecal-oral route. Some people continue to shed the bacterium that
50	causes typhoid (Salmonella enterica serovar Typhi, or S. Typhi) after recovering from the illness. To
51	stop onward spread it is important that these people are identified and treated.
52	Shedders are detected when S. Typhi grows from faeces, but it is not practical to obtain stool samples
53	from large populations. Following a typhoid outbreak we tested whether a subset of participants with
54	high antibodies to S. Typhi proteins contained more shedders than a subset with low antibody
55	responses. We tested whether antibody levels changed in the months after the outbreak, to inform
56	whether they are useful markers of exposure in a population.
56 57	whether they are useful markers of exposure in a population. We did not grow <i>S</i> . Typhi. This may be because our population had few risk factors for <i>S</i> . Typhi
57	We did not grow S. Typhi. This may be because our population had few risk factors for S. Typhi
57 58	We did not grow <i>S</i> . Typhi. This may be because our population had few risk factors for <i>S</i> . Typhi carriage, or because exposure to other endemic bacteria influence antibody levels. We saw a decline
57 58 59	We did not grow <i>S</i> . Typhi. This may be because our population had few risk factors for <i>S</i> . Typhi carriage, or because exposure to other endemic bacteria influence antibody levels. We saw a decline in antibody levels over time, most marked in those who reported fever during the outbreak. We think

63 Background

It is estimated that 1.5 million cases of typhoid fever occurred in Sub-Saharan Africa in 2017 (1). Whilst this figure represents a fall in incidence estimates from 1990, localised outbreaks (2-5) map closely to the emergence of genotypes associated with multi-drug resistance (MDR) (6). Mathematical modelling suggests such outbreaks may be driven by increased transmissibility associated with drug resistance phenotypes (7). Where *Salmonella* enterica serovar Typhi (*S*. Typhi) is inadequately treated, ongoing shedding becomes more likely, and detection of this is essential in order to break the transmission cycle.

71 S. Typhi is shed intermittently in stool, and bacterial culture lacks sensitivity (8). A recent case-

72 control study of children living in Nairobi found *S*. Typhi carriage rates of 1.1% among asymptomatic

4

individuals (9). The relative contribution of temporary shedders to ongoing transmission remains
unclear, but is likely to play a larger role in high incidence settings (10, 11).

In non-endemic settings, serology has been exploited to complement an outbreak investigation, with
candidate shedders successfully identified by a high anti-Vi antibody titre (anti-Vi IgG) followed by
isolation of *S*. Typhi in stool (12, 13). Serology has been used in attempts to identify carriers in
endemic populations, but has shown limited success (14-16).

79 In June 2016 an outbreak of febrile illness occurred in Malosa, Malawi. Three patients presenting to

80 the local hospital had blood culture-confirmed typhoid fever. Cases were traced to a local primary

school, secondary school and a residential nursing school. Over the next month the District Health

82 Office identified 101/407 nursing school residents who met a clinical case definition for typhoid

83 fever.

84 Our primary objective was to identify nursing school residents shedding S. Typhi after the outbreak,

using serology to target subsequent testing of high risk individuals. We focussed our efforts on the

86 nursing school because students continuing to shed S. Typhi might transmit typhoid to patients.

87 Secondary objectives were to identify any environmental source of S. Typhi within the nursing school

and to explore serologic responses to typhoid exposure, as determined by self-reported, persistent

89 fever.

90

91 Methods

We performed a prospective observational study comprising two study visits, conducted three and sixmonths after the Malosa outbreak.

Any person over 18 years of age who had been resident in the nursing school between 1st June 2016
and 31st August 2016 was eligible to participate. We enrolled participants and conducted study visit
one simultaneously in October 2016, three months after the outbreak.

We collected a blood sample from each participant and completed a structured case record. This

5

the

98	included self-report of whether the participant had a persistent fever (defined as three days or more
99	duration) during the outbreak. Those with persistent fever were considered typhoid cases based on t
100	WHO case finding definition (17).
101	We identified participants whose three-month anti-Vi IgG levels were in the top ten percent of the
102	cohort and participants whose anti-Vi IgG were in the lowest ten percent of the cohort. These
103	participants were approached and asked to provide a stool sample. Samples were collected between
104	the three- and six-month study visits, after anti-Vi IgG results became available. Stool was sent for
105	culture and polymerase chain reaction (PCR) testing.
106	The entire cohort was approached again in January 2017, six months after the outbreak. A further
107	blood sample was obtained for repeat serology.

108 *Laboratory procedures*

- 109 We determined anti-Vi IgG antibody concentration using a commercial Enzyme-linked
- 110 immunosorbent assay (ELISA) in accordance with manufacturer's instructions (VaccZyme[™] The
- 111 Binding Site, Birmingham, UK). We derived antibody concentration in ELISA units/ml (EU/ml) from
- the optical density using a standardised curve-fitting logistic method.
- 113 Anti-H:d IgM and IgG were performed at the Oxford University Clinical Research Unit in Vietnam,
- using in-house ELISAs, as previously described (18).
- 115 Stool samples were collected in sterile sample pots and transferred to the laboratory on the same day.
- 116 Stool was pre-enriched in Selenite broth before being sub-cultured on Xylose Lysine Deoxyxholate
- 117 (XLD) agar at 37°C for 18-24 hours. Single colonies from XLD were sub-cultured on MacConkey
- and Sheep blood agar (SBA) plates. Colonies from SBA plates were used for biochemical tests.
- 119 Analytical Profile Index (API 20E) tests were used for *Salmonella* identification. Following the
- 120 White-Kauffmann-Le Minor scheme, serotyping was done using polyvalent O and H, O4, O9, Hd,
- 121 Hg, Hi, Hm, and Vi antisera (Pro-Lab Diagnostics).

6

PCR testing was used alongside routine culture to increase the yield from stool. DNA was extracted
from Selenite broth pre-enriched stool specimens using QIAamp Fast DNA Stool Mini Kit (Qiagen).
A pan *Salmonella* PCR targeting the *ttr* gene, encoding tetrathionate reductase, and a multiplex PCR

- 125 with a pan-Salmonella invasion A gene, S. Typhi fimbriae gene, and the kit's internal control were
- 126 performed (19, 20).
- 127

128 Environmental sampling

129 Malosa Dam provides water for the nursing school and secondary school via a gravity fed water pipe

130 feeding in to a holding tank. The water is reportedly chlorinated daily after leaving the holding tank.

131 We took 36 environmental samples, in-duplicate, over two days. These comprised stool from food-

handlers, food and tap water from the kitchens and water from the dam. Samples were cultured and

133 sero-typed as described above.

134 *Statistical methods*

We treated serologic data as a metric continuous variable, and our surrogate measure of typhoid exposure as dichotomous (fever for \geq 3 days or not).

137 We tested continuous variables for normality using the Shapiro-Wilks test before and after log-138 transformation. We used nonparametric tests where data were not normally distributed.

139 We used paired significance tests to compare change in antibody titre within the population as a

140 whole and change in antibody titre depending upon whether the clinical definition for typhoid had

141 been met. We used unpaired significance tests to compare antibody titres between participants who

- 142 did and did not meet the WHO definition for typhoid at each study visit. Only participants who
- submitted serum at three and six months contributed to paired analyses.
- Statistical analyses were carried out using the free to use, open source statistical package 'R' version
 4.1.1 (21). The significance threshold was set at 0.05 for all tests.

Ethical considerations

148	All participants provided written informed consent. Participant information materials were made
149	available in English and Chichewa languages. Our protocol stated that those who were stool culture
150	positive for S. Typhi would be advised by the District Health Office to take either 28 days of
151	ciprofloxacin or 14 days of azithromycin with the aim of eradicating carriage and preventing onward
152	transmission. This study was approved by College of Medicine Research Ethics Committee,
153	P.10/16/2043.
154	
155	Results
156	We recruited 374 participants from a total population of 407. 368 participants submitted blood
157	samples three months post outbreak. 320 participants submitted blood at three months and six months.
158	We obtained stool samples from 25 of 36 participants whose anti-Vi IgG response was in the highest
159	decile, and from 24 of 36 participants whose anti-Vi IgG response was in the lowest decile. The
160	characteristics of included participants are shown in Table one.
161	
162	

	Clinical typhoid	No clinical typhoid	
Participants (N)	156	212	
Age in years (mean)	22.6	24.2	
(range)	8-54	18-42	
(SD)	4.4	6.3	
gender (proportion female, (%))	78/156 (50)	106/212 (50)	
Treated with antibiotics (%)	140/156 (90)	16/212 (7.5)	
Median anti-Vi IgG titre	8.08 (IQR 17.9)	3.7 (IQR 12.4)	P =0.11 (Mann-
at visit one (EU/ml)			Whitney-U test)
Median anti-H:d IgM	55.2 (IQR 51.4)	52.1 (IQR 55.9)	P=0.34 (Mann-
antibody titre at visit one (EU/ml)			Whitney-U test)
Median anti-H:d IgG antibody titre at visit	87.8 (IQR 85.1)	82.4 (IQR 88.4)	P = 0.27 (Mann-
one (EU/ml)			Whitney-U test)
Median anti-Vi IgG titre at visit two (EU/ml)	3.7 (IQR 17.7)	3.7 (IQR14.4)	P=0.86 (Mann-
			Whitney-U test)
Median anti-H:d IgM	54.2 (IQR 44.9)	55.3 (IQR 56.1)	P=0.92 (Mann-
antibody titre at visit two (EU/ml)			Whitney-U test)
Median anti-H:d IgG	77.4 (IQR 57)	79.2 (IQR 65.7)	P=0.80 (Mann-
antibody titre at visit two (EU/ml)			Whitney-U test)
Headache, N (%)	139/156 (89)	39/212 (18.4)	
Abdominal pain, N (%)	82/156 (52.6)	25/212 (11.8)	1
Diarrhoea, N (%)	62/156 (39.7)	29/212 (13.7)	
Constipation, N (%)	31/156 (19.9)	10/212 (4.7)	1
Nausea, N (%)	60/156 (38.5)	13/212 (6.1)	

Table 1. Baseline characteristics of participants who submitted blood samples at study visit one 171

172 Stool Culture

- 173 Of 49 participants who submitted stool for culture, none were culture positive for S. Typhi in stool.
- Four participants had Salmonella spp. in stool on routine culture. Three of these participants were in 174
- the lowest decile for anti-Vi IgG level at visit one, one was in the highest decile. None of the stool 175
- 176 samples grew S. Typhi (Figure 1). Ttr and multiplex PCR test did not detect any additional
- 177 Salmonella from the stool samples. One Salmonella isolate was identified as S. Typhi using the S.
- 178 Typhi fimbriae gene target on the multiplex PCR. This participant had the highest three-month anti-Vi
- 179 IgG and anti-H:d IgG titres among participants submitting stool. (Supplemental Figures 1-3).

180

- 181 Figure 1. A. Log anti-Vi IgG concentration at the three month visit among participants who grew Salmonella spp. in stool (purple)
- 182 compared with those who had no growth (turquoise). B. log anti-H:d IgM concentration at the three month visit among participants who
- 183 grew Salmonella spp. in stool (green) compared with those who did not (red). C. log anti-H:d IgG concentration at the three month visit
- 184 among participants who grew Salmonella spp. in stool (brown) and those who did not (black).
- 185

Antibody responses 186

Among participants with persistent fever there was a significant fall in anti-Vi IgG between three and 187 six months (median titre 8.08 to 3.7 EU/ml (p = <0.000001, Wilcoxon signed rank test). This was not 188 true of participants without persistent fever (median titre 3.7 to 3.7 EU/ml, p = 0.12, Wilcoxon signed 189 190 rank test) (Figure 2.)

- 191 Figure 2. A. log anti-Vi IgG concentration amongst participants with persistent fever, comparing titres at 3 months (lilac) and 6 months
- 192 (turquoise) post-outbreak. B. log anti-Vi IgG concentration amongst participants without persistent fever, comparing titres at 3 months
- 193 (lilac) and 6 months (turquoise) post-outbreak. C. log anti-H:d IgM concentration amongst participants with persistent fever, comparing
- 194 titres at 3 months (beige) and 6 months (yellow) post-outbreak. D. log anti-H:d IgM concentration amongst participants without persistent
- 195 fever, comparing titres at 3 months (beige) and 6 months (yellow) post outbreak. E. log anti-H:d IgG concentration amongst participants
- 196 without persistent fever, comparing titres at 3 months (green) and 6 months (purple) post-outbreak. F. log anti-H:d IgM concentration
- 197 amongst participants without persistent fever, comparing titres at 3 months (green) and 6 months (purple) post-outbreak. All graphs: red
- 198 crossbar shows median antibody concentration; brackets show p-values (Wilcoxon signed rank test).

10

200	Among participants with persistent fever there was a significant fall in anti-H:d IgG between three
201	and six months (median titre 87.8 to 77.4 EU/ml ($p = 0.0002$, Wilcoxon signed rank test). Among
202	participants without persistent fever, there was also a significant fall in anti-H:d IgG between three
203	and six months (median titre 82.4 to 79.2 EU/ml, $p = 0.006$, Wilcoxon signed rank test) (Figure 2.)
204	There was no significant change in anti-H:d IgM between three and six months, either among those
204 205	There was no significant change in anti-H:d IgM between three and six months, either among those with persistent fever (median titre 55.2 to 54.2 EU/ml ($p = 0.33$, Wilcoxon signed rank test) or

208

209 Environmental Sampling

210 Non-typhoidal *Salmonella* was identified from tap water in the kitchen of the nursing school and in
211 water from Malosa dam. No *S*. Typhi was identified.

212 Discussion

Our study shows that, even in a population enriched through the circumstances of an outbreak, sero-213 surveillance could not identify culture-confirmed shedding of S. Typhi. Sero-surveillance combined 214 with PCR may have identified one participant shedding S. Typhi. Anti-Vi IgG titres fell amongst 215 participants reporting persistent fever during the outbreak. Anti-H:d IgG titres fell amongst 216 participants with and without persistent fever. There was no change in anti-H:d IgM, irrespective of 217 218 fever status. We did not find an environmental reservoir of S. Typhi, but non-typhoidal salmonellae were present in water samples from the reservoir supplying the nursing school, and a tap in the 219 220 kitchen. The presence of these bacteria indicate contamination and under-treatment of the water 221 supply, and represent a possible source of the outbreak.

As our population was pre-defined, we could not perform an *a priori* power calculation. Our study population was young (mean 23.5 years). We expect low rates of biliary pathology in the population based on discussions with surgical colleagues working in the area. A similar study design might have

11

detected *S*. Typhi shedding amongst an older cohort, or in an endemic setting where rates of biliarydisease are high.

227 Participants from the Nursing College were on clinical placement in multiple institutions across 228 Southern Malawi. This made enrolment and follow-up challenging: we were unable to obtain stool samples from all the participants that we identified in the highest and lowest anti-Vi IgG titre groups. 229 Given the intermittent nature of shedding, several samples over time would have increased our 230 chances of detecting S. Typhi by culture. One participant was identified as having PCR amplification 231 of the *fimbriae* target. This suggests that they may have been carrying / shedding S. Typhi, but this 232 233 could not be verified through culture confirmation. This participant had the highest anti-Vi IgG and anti-H:d IgG titres of all those who submitted stool. 234

The fall in anti-Vi IgG and anti-H:d IgG suggests that a peak titre is reached within the post outbreak surveillance period encompassed by our study, and that titres have fallen six months post exposure. It is possible that anti-Vi IgG is more specific to febrile typhoid illness, or that anti-H:d IgG falls more swiftly after exposure and so an effect was demonstrable across the entire cohort. This would be in keeping with findings from a human challenge model (22). The static anti-H:d IgM concentration suggests that any change in titre precipitated by the outbreak has been and gone at three months.

241 The Vi (virulence) antigen comprises a polysaccharide expressed on the surface of S. Typhi, as well 242 as Salmonella Paratyphi C, Citrobacter freundii and Salmonella Dublin (23, 24). IgG antibodies to 243 the Vi antigen have been detected in high titres among microbiologically confirmed shedders of S. 244 Typhi (14, 25, 26). S. Typhi shedders have been identified through their high anti-Vi titre in the 245 context of two outbreaks in the United States (12, 13). Yet the role of anti-Vi IgG for population screening for Typhoid shedding remains unclear: a 2004 study obtained sera from 3209 adults in a 246 247 Typhoid-endemic area (Vietnam). Multiple rectal swabs were taken from 103 participants with the highest anti-Vi IgG titres at different time points and no S. Typhi was isolated (15). Although we 248 obtained fewer faecal specimens, our study population was 'enriched' by a known recent exposure to 249 typhoid. The paucity of S. Typhi detection in both settings suggests that anti-Vi IgG might be elevated 250 for reasons other than biliary carriage, such as cross-reactivity with other bacteria that express the Vi 251

12

252	antigen, or convalescence from acute typhoid fever. It is plausible that both factors would be more
253	significant in areas of the world where typhoid fever is endemic, explaining the geographical
254	discrepancy. A Chilean study comparing anti-Vi IgG amongst bacteriologically proven S. Typhi
255	carriers and healthy control subjects and those with acute typhoid fever supports our finding that anti-
256	Vi IgG is a non-specific marker in an endemic setting: although the authors demonstrated higher
257	antibody titre among the shedders, one quarter of chronic carriers did not have a high anti-Vi IgG titre
258	(14).
259	A recent study utilising culture confirmed carriers who underwent cholecystectomy in Nepal found 13
260	putative antigens in sera that were expressed highly in the carrier state, and which might bear closer
261	scrutiny in future studies looking for shedding (27). Future studies should focus on robust
262	microbiological confirmation of S. Typhi shedding status to provide clear comparators for prospective
263	serologic markers. The detection of carriers will require repeated stool sampling over time, and newer
264	PCR techniques may increase sensitivity over culture alone (19, 28).
265	Despite the success of conjugate typhoid vaccines in preventing typhoid cases, the recent cluster
266	randomised trial in Bangladesh has yet to show significant indirect protection (29). Wider public
267	health measures, including identifying those who continue to shed S. Typhi after infection, remain key
268	to reducing transmission and to ultimately eradicating typhoid.

269 Funding

270 This research was supported by a grant from the Bill and Melinda Gates Foundation.

271 References

 Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, et al. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Infectious Diseases. 2019;19(4):369-81.

Feasey NA, Gaskell K, Wong V, Msefula C, Selemani G, Kumwenda S, et al. Rapid
 emergence of multidrug resistant, H58-lineage Salmonella typhi in Blantyre, Malawi. PLoS neglected
 tropical diseases. 2015;9(4):e0003748.

Davis WW, Chonzi P, Masunda KP, Shields LM, Mukeredzi I, Manangazira P, et al. Notes
 from the field: typhoid fever outbreak—Harare, Zimbabwe, October 2016–March 2017. Morbidity
 and Mortality Weekly Report. 2018;67(11):342.

Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, Lukwesa-Musyani C, Tambatamba B,
 Mwaba J, et al. Genomic signature of multidrug-resistant Salmonella enterica serovar Typhi isolates

283	related to a massive outbreak in Zambia between 2010 and 2012. Journal of clinical microbiology.
284	2015;53(1):262-72.
285	5. Lutterloh E, Likaka A, Sejvar J, Manda R, Naiene J, Monroe SS, et al. Multidrug-resistant
286	typhoid fever with neurologic findings on the Malawi-Mozambique border. Clinical infectious
287	diseases. 2012;54(8):1100-6.
288	6. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The phylogeography and
289	incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. Nature communications.
290	2018;9(1):1-10.
291	7. Pitzer VE, Feasey NA, Msefula C, Mallewa J, Kennedy N, Dube Q, et al. Mathematical
292	modeling to assess the drivers of the recent emergence of typhoid fever in Blantyre, Malawi. Clinical
293	Infectious Diseases. 2015;61(suppl_4):S251-S8.
294	8. Braddick MR, Crump BJ, Yee ML. How long should patients with Salmonella typhi or
295	Salmonella paratyphi be followed-up? A comparison of published guidelines. Journal of Public
296	Health. 1991;13(2):101-7.
297	9. Kariuki S, Dyson ZA, Mbae C, Ngetich R, Kavai S, Wairimu C, et al. Multiple introductions
298	of multidrug-resistant typhoid associated with acute infection and asymptomatic carriage, Kenya.
299	bioRxiv. 2021.
300	10. Luxemburger C, Duc CM, Lanh MN, Wain J, Hien TT, Simpson JA, et al. Risk factors for
301	typhoid fever in the Mekong delta, southern Viet Nam: a case-control study. Transactions of the
302	Royal Society of Tropical Medicine and Hygiene. 2001;95(1):19-23.
303	11. Crump JA. Progress in typhoid fever epidemiology. Clinical Infectious Diseases.
304	2019;68(Supplement_1):S4-S9.
305	12. Lin F, Becke J, Groves C, Lim B, Israel E, Becker E, et al. Restaurant-associated outbreak of
306	typhoid fever in Maryland: identification of carrier facilitated by measurement of serum Vi
307	antibodies. Journal of clinical microbiology. 1988;26(6):1194-7.
308	13. Engleberg N, Barrett T, Fisher H, Porter B, Hurtado E, Hughes J. Identification of a carrier by
309	using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever on an Indian
310	reservation. Journal of clinical microbiology. 1983;18(6):1320-2.
311	14. Lanata C, Ristori C, Jimenez L, Garcia J, Levine M, Black R, et al. Vi serology in detection
312	of chronic Salmonella typhi carriers in an endemic area. The Lancet. 1983;322(8347):441-3.
313	15. Gupta A, Thanh NM, Olsen S, Sivapalasingam S, Trinh TM, Lan NP, et al. Evaluation of
314	community-based serologic screening for identification of chronic Salmonella typhi carriers in
315	Vietnam. International journal of infectious diseases. 2006;10(4):309-14.
316	16. Khanam F, Darton TC, Meiring JE, Sarker PK, Biswas PK, Bhuiyan MAI, et al. Salmonella
317	Typhi stool shedding by enteric fever patients and asymptomatic chronic carriers in an endemic urban
318	setting. Journal of Infectious Diseases. 2021.
319	17. WHO. Typhoid and other invasive salmonellosis. Vaccine-Preventable Diseases Surveillance
320	Standards. Geneva, Switzerland: World Health Organization; 2020.
321	18. Thieu NTV, Van TT, Tuan AT, Klemm EJ, Minh CNN, Vinh PV, et al. An evaluation of
322	purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever.
323	Journal of Infection. 2017;75(2):104-14.
324	19. Chirambo AC, Nyirenda TS, Jambo N, Msefula C, Kamng'ona A, Molina S, et al.
325	Performance of molecular methods for the detection of Salmonella in human stool specimens.
326	Wellcome open research. 2020;5.
327	20. Msefula CL, Olgemoeller F, Jambo N, Segula D, Van Tan T, Nyirenda TS, et al. Ascertaining
328	the burden of invasive Salmonella disease in hospitalised febrile children aged under four years in
329	Blantyre, Malawi. PLoS neglected tropical diseases. 2019;13(7):e0007539.


14


330	21. Team RC. R: a language and environment for statsistical computing. 4.1.0 ed. Vienna,
331	Austria: R Foundation for Statistical Computing; 2021.
332	22. Darton TC, Baker S, Randall A, Dongol S, Karkey A, Voysey M, et al. Identification of novel
333	serodiagnostic signatures of typhoid fever using a Salmonella proteome array. Frontiers in
334	microbiology. 2017;8:1794.
335	23. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella chronic
336	carriage: epidemiology, diagnosis, and gallbladder persistence. Trends in microbiology.
337	2014;22(11):648-55.
338	24. Hu X, Chen Z, Xiong K, Wang J, Rao X, Cong Y. Vi capsular polysaccharide: Synthesis,
339	virulence, and application. Critical reviews in microbiology. 2017;43(4):440-52.
340	25. Nolan CM, Feeley JC, White Jr PC, Hambie EA, Brown SL, Wong K-H. Evaluation of a new
341	assay for Vi antibody in chronic carriers of Salmonella typhi. Journal of clinical microbiology.
342	1980;12(1):22-6.
343	26. Losonsky GA, Ferreccio C, Kotloff KL, Kaintuck S, Robbins J, Levine M. Development and
344	evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic
345	Salmonella typhi carriers. Journal of clinical microbiology. 1987;25(12):2266-9.
346	27. Charles RC, Sultana T, Alam MM, Yu Y, Wu-Freeman Y, Bufano MK, et al. Identification of
347	immunogenic Salmonella enterica serotype Typhi antigens expressed in chronic biliary carriers of S.
348	Typhi in Kathmandu, Nepal. PLoS neglected tropical diseases. 2013;7(8):e2335.
349	28. Nair S, Patel V, Hickey T, Maguire C, Greig DR, Lee W, et al. Real-time PCR assay for
350	differentiation of typhoidal and nontyphoidal Salmonella. Journal of clinical microbiology.
351	2019;57(8):e00167-19.
352	29. Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, et al. Protection by
353	vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban
354	Bangladesh: a cluster-randomised trial. The Lancet. 2021;398(10301):675-84.

355

Supplemental Figures 356

- 357 Supplemental Figure 1. A. Log anti-Vi IgG concentration at the three month visit among participants who did and did not amplify the
- 358 fimbriae PCR target from stool. Green coloured dots represent participants who were culture-negative for Salmonella spp. from stool,
- 359 turquoise coloured dots represent those who were culture-positive for Salmonella spp from stool. B. log anti-H:d IgM at the three month
- 360 visit among participants who did and did not amplify the fimbriae PCR target from stool. Yellow coloured dots represent participants who
- 361 were culture-negative for Salmonella spp. from stool, purple coloured dots represent those who were culture-positive for Salmonella spp
- 362 from stool. C. log anti-H:d IgG at the three month visit among participants who did and did not amplify the fimbriae PCR target from stool.
- 363 Orange coloured dots represent participants who were culture-negative for Salmonella spp. from stool, grey coloured dots represent those
- 364 who were culture-positive for Salmonella spp from stool.








Figure 1